Dabrafenib and trametinib therapy in an elderly patient with non‐small cell lung cancer harboring the BRAF V600E mutation

Dabrafenib and trametinib therapy for BRAF V600E‐mutant non‐small cell lung cancer (NSCLC) has demonstrated strong antitumor effects in clinical trials and has been approved for use in clinical practice. However, the efficacy and safety of this combination therapy in elderly patients remain unclear....

Descripción completa

Detalles Bibliográficos
Autores principales: Dotsu, Yosuke, Fukuda, Minoru, Honda, Noritaka, Gyotoku, Hiroshi, Kohno, Yoshihisa, Suyama, Takayuki, Umeyama, Yasuhiro, Taniguchi, Hirokazu, Takemoto, Shinnosuke, Yamaguchi, Hiroyuki, Miyazaki, Taiga, Sakamoto, Noriho, Obase, Yasushi, Ikeda, Hiroaki, Ashizawa, Kazuto, Mukae, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812073/
https://www.ncbi.nlm.nih.gov/pubmed/33215864
http://dx.doi.org/10.1111/1759-7714.13756

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812073/
https://www.ncbi.nlm.nih.gov/pubmed/33215864
http://dx.doi.org/10.1111/1759-7714.13756

Ejemplares similares